BofA Securities Defending Kenvue Inc (KVUE): 'We estimate Tylenol represents ~9% of KVUE’s sales', Sees 'widening discount as a particularly attractive entry point'
Tweet Send to a Friend
BofA Securities analyst Anna Lizzul reiterated a Buy rating and $25.00 price target on Kenvue Inc (NYSE: KVUE).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
